Antex, SmithKline deal
The companies restructured their 1996 agreement to develop infectious disease vaccines, dissolving their joint venture, MicroCarb Human Vaccines (see BioCentury, May 13, 1996). Under the agreement, SmithKline had an exclusive worldwide license to any human infectious disease vaccines from the joint venture.
Going forward, SmithKline will receive exclusive rights only to certain ANTX human vaccines. The companies will continue to develop the remaining vaccines. ANTX will continue to receive R&D funding and remains eligible for milestones and royalties. ANTX will develop internally and license out the reacquired vaccines. SmithKline is eligible to receive royalties on certain vaccines sold by ANTX and to receive a portion of the proceeds if ANTX elects to out-license certain vaccines. ...